The phase 1/2 CHRYSALIS study demonstrated that single-agent gilteritinib had a favorable safety profile and, at ≥ 80-mg/day doses, induced ≥ 90% inhibition of FLT3 autophosphorylation with a composite complete remission (CRc) rate of 41% in patients with R/R FLT3mut+ AML [26]. The gene discussed is FLT3; the disease is acute myeloid leukemia.